## nature portfolio

Corresponding author(s):	Michael Stowell; Ryan Hibbs	
Last updated by author(s):	1/27/2022	

## **Reporting Summary**

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our <u>Editorial Policies</u> and the <u>Editorial Policy Checklist</u>.

<b>~</b> .			
St	at.	ict	ICC

Statistics					
For all statistic	cal analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.				
n/a Confirme	ed				
The	exact sample size $(n)$ for each experimental group/condition, given as a discrete number and unit of measurement				
☐ X A sta	stement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly				
IVIII	statistical test(s) used AND whether they are one- or two-sided common tests should be described solely by name; describe more complex techniques in the Methods section.				
A de	scription of all covariates tested				
A de	A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons				
☐ ☐ A ful	A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient)  AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)				
	For null hypothesis testing, the test statistic (e.g. <i>F</i> , <i>t</i> , <i>r</i> ) with confidence intervals, effect sizes, degrees of freedom and <i>P</i> value noted <i>Give P values as exact values whenever suitable.</i>				
For E	For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings				
For h	For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes				
Estin	nates of effect sizes (e.g. Cohen's $d$ , Pearson's $r$ ), indicating how they were calculated				
,	Our web collection on <u>statistics for biologists</u> contains articles on many of the points above.				
Software	and code				
Policy informa	ation about <u>availability of computer code</u>				
Data collect	ion SerialEM, pCLAMP 10.7				
Data analys	Relion 3.1, Phenix 1.19.2-4158, UCSF Chimera 1.15, ChimeraX 1.1.1., crYOLO 1.7.6, Pymol 2.5.1, GraphPad Prism 9.1.2, Molprobity 4.5.1				

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio guidelines for submitting code & software for further information.

## Data

Policy information about availability of data

All manuscripts must include a data availability statement. This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our policy

Cryo-EM maps and atomic model coordinates have been deposited in the EMDB and RCSB respectively; apo (EMDB: EMD-25202 and PDB: 7SMM), apo plus cholesterol (EMDB: EMD-25205 and PDB: 7SMQ), carbachol-bound desensitized state: (EMDB: EMD-25202 and PDB: 7SMM), d-tubocurarine bound: (EMDB: EMD-25207 and PDB: 7SMS) and d-tubocurarine plus carbachol bound: (EMDB: EMD-25208 and PDB: 7SMT). PDB 6UWZ was used as initial model.

Field-spe	ecific re	eporting		
Please select the o	ne below that i	s the best fit for your research. If you are not sure, read the appropriate sections before making your selection.		
\times Life sciences	E	Behavioural & social sciences		
For a reference copy of	the document with	all sections, see <a href="nature.com/documents/nr-reporting-summary-flat.pdf">nature.com/documents/nr-reporting-summary-flat.pdf</a>		
Life scier	nces sti	udy design		
All studies must dis	sclose on these	points even when the disclosure is negative.		
Sample size	For each Cryo-EM dataset, data were collected from ~24 hrs microscope time, which was sufficient for reconstructing a high-resolution density map. For electrophysiological data, sample sizes were selected to maximize statistical significance while considering the experimental setup and published literature.			
Data exclusions	No data were e	were excluded from the analyses.		
Replication	All electrophys condition.	ophysiological data were replicated using independent cells and were performed over different days of recording. n=4-8 cells per 1.		
Randomization	The cells for ele	the cells for electrophysiological experiments were chosen randomly.		
Blinding	None.			
Reportin	g for si	pecific materials, systems and methods		
We require informati	ion from authors	about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.		
Materials & ex	perimental s	ystems Methods		
n/a Involved in th	ed in the study n/a   Involved in the study			
Antibodies	Antibodies ChIP-seq			
Eukaryotic		Flow cytometry		
Palaeontology and archaeology MRI-based neuroimaging				
Animals and other organisms				
Human research participants				
Clinical data  Dual use research of concern				
ZI Dadi ase it	escurer or correc			
Eukaryotic c	cell lines			
Policy information	about <u>cell lines</u>			
Cell line source(s	5)	HEK293S GnTI- was purchased from ATCC (CRL-3022).		
Authentication	Authenticated by ATCC			
Mycoplasma con	ntamination	tion Tested negative by ATCC.		

No commonly misidentified cell lines were used.

Commonly misidentified lines (See <u>ICLAC</u> register)